Division of Gastroenterology & Hepatology Research

Our research goals at NYU Langone’s Division of Gastroenterology and Hepatology are to provide access to the latest treatments in the pipeline to our patients and to advance knowledge of gastroenterology and hepatology through innovative basic science, translational research, and clinical trials. We aim to foster a spirit of scientific inquiry and innovation among faculty, fellows, and students.
Our researchers study the biology, prevention, diagnosis, and treatment of gastrointestinal (GI) and liver diseases. Among our current areas of research are the following:
- role of the gut microbiome in health and the pathogenesis of disease such as colorectal cancer, liver cancer, and fatty liver and other diseases
- role of GI infection and gut microbial dysbiosis in the pathogenesis of inflammatory bowel disease
- quality and innovations in enhanced technologies for colon cancer screening
- bariatric endoscopy outcomes in obesity and fatty liver disease
- clinical trials in all areas of liver disease, inflammatory bowel disease, colorectal cancer screening and prevention, and other GI conditions
- cirrhosis and hepatitis C infection
Select Faculty Publications
Esophageal Disorders in the Older Adult
Current treatment options in gastroenterology. 2025 Dec ; 23:
Current Perspectives on Colorectal Cancer Screening and Surveillance in the Geriatric Population
Current gastroenterology reports. 2025 Jun 02; 27:34
Clinical Validation of a Circulating Tumor DNA-Based Blood Test to Screen for Colorectal Cancer
JAMA. 2025 Jun 02;
Right-Sided Dysplasia in Inflammatory Bowel Disease Is Not Associated with Conventional Risk Factors for Neoplasia
Gastroenterology insights. 2025 Jun ; 16:
PCR-based stool testing for enteric infections in flares of inflammatory bowel disease: Is more data worth the cost? [Editorial]
Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology. 2025 May 16;
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial
Journal of hepatology. 2025 May 08;
Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) in 4 major cities in the United States
Hepatology communications. 2025 May 01; 9:
Graying of IBD in the US-An Urgent Call to Action [Editorial]
Digestive diseases and sciences. 2025 Apr 29;